de Villiers J N, Hillerman R, de Jong G, Langenhoven E, Rossouw H, Marx M P, Kotze M J
Department of Obstetrics and Gynaecology, University of Stellenbosch.
S Afr Med J. 1999 Mar;89(3):279-82.
The aim of the study was to investigate the molecular basis of hereditary haemochromatosis (HH) in South Africa in order to establish a reliable, cost-effective molecular diagnostic service for this potentially lethal disorder.
DNA samples of patient and control groups were screened for two common haemochromatosis (HFE) gene mutations. The local frequencies of mutations C282Y and H63D were determined and the DNA results correlated with biochemical parameters.
Patients were referred from private practitioners, health workers and pathologists for a molecular diagnosis of HH at the University of Stellenbosch Medical School. Twenty-two of the 244 referrals were clinically diagnosed with HH, while the remaining patients were family members of the probands or unrelated subjects referred solely on the basis of an abnormal iron profile.
Seventeen of the 22 patient referrals (77%) diagnosed with HH were homozygous for the C282Y mutation, 3 (14%) were compound heterozygotes for mutations C282Y and H63D, and 2 patients (9%) did not exhibit either mutation. Screening of 458 control individuals from the general South African population demonstrated a carrier frequency of approximately 17% for the C282Y mutation among whites, implying that up to 1 out of every 115 South Africans of European descent may be homozygous for this founder-type mutation. Among 64 healthy blood donors of mixed ancestry, we detected 2 individuals heterozygous and 1 homozygous for the C282Y mutation.
The detection of mutations C282Y and H63D at a high frequency in the majority of affected South African patients facilitates accurate pre-clinical and confirmatory diagnosis of HH in South Africa. Early detection by DNA screening and subsequent treatment by repeated phlebotomy can prevent disease onset in affected individuals. DNA diagnosis is particularly applicable to a common genetic disease such as HH, which is underdiagnosed and potentially lethal, but treatable.
本研究旨在探究南非遗传性血色素沉着症(HH)的分子基础,以便为这种潜在致命性疾病建立可靠且经济高效的分子诊断服务。
对患者组和对照组的DNA样本进行两种常见血色素沉着症(HFE)基因突变的筛查。确定突变C282Y和H63D的本地频率,并将DNA检测结果与生化参数相关联。
患者由私人执业医生、卫生工作者和病理学家转介至斯泰伦博斯大学医学院进行HH的分子诊断。244例转介患者中,22例临床诊断为HH,其余患者为先证者的家庭成员或仅因铁代谢指标异常而转介的无关个体。
22例临床诊断为HH的转介患者中,17例(77%)为C282Y突变纯合子,3例(14%)为C282Y和H63D突变的复合杂合子,2例患者(9%)未表现出任何突变。对458名来自南非普通人群的对照个体进行筛查发现,白人中C282Y突变的携带频率约为17%,这意味着每115名欧洲裔南非人中可能有1人是这种奠基者型突变的纯合子。在64名混合血统的健康献血者中,我们检测到2例C282Y突变杂合子和1例纯合子。
在大多数受影响的南非患者中高频检测到C282Y和H63D突变,有助于在南非对HH进行准确的临床前诊断和确诊。通过DNA筛查早期发现并随后通过反复放血进行治疗,可以预防受影响个体发病。DNA诊断特别适用于HH这种常见的遗传疾病,它诊断不足且具有潜在致命性,但可治疗。